SCHEMBL718690

SCHEMBL718690

Cc1c(C(=O)C2CCCCC2)sc2ncccc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.45
CHUK O15111 1/20 0.45
LIMK1 P53667 1/20 0.45
TP53 P04637 2/20 0.43
CYP2C19 P33261 2/20 0.41
ELANE P08246 3/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
THRB P10828 1/20 0.38
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724156 0.79 LIMK1 (0.45) LIMK1TP53CYP2C19ALDH1A1HPGD
SCHEMBL843920 0.77 KDM4E (0.56) IKBKBCHUKLIMK1TP53CYP2C19
SCHEMBL717434 0.76 PRNP (0.51) IKBKBLIMK1CYP2C19KDM4EALDH1A1
SCHEMBL20723069 0.76 LIMK1 (0.69) IKBKBCHUKLIMK1TP53KDM4E
SCHEMBL718685 0.74 ESR1 (0.40) TP53CYP2C19KDM4EALDH1A1HPGD
SCHEMBL719608 0.74 KDM4E (0.44) TP53CYP2C19KDM4EALDH1A1HPGD
SCHEMBL1810663 0.73 TP53 (0.67) IKBKBCHUKLIMK1TP53CYP2C19
SCHEMBL719584 0.72 KDM4E (0.58) IKBKBCHUKLIMK1TP53CYP2C19
SCHEMBL9541065 0.72 ALDH1A1 (0.46) IKBKBCHUKLIMK1TP53CYP2C19
SCHEMBL9542550 0.71 RAB9A (0.50) CYP2C19KDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP IKBKB 111/4885CHUK 19/4885LIMK1 4140/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP IKBKB 111/4885CHUK 19/4885LIMK1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.